Tsakos Energy Navigation Ltd
Change company Symbol lookup
Select an option...
TNP-F Tsakos Energy Navigation Ltd
ANEB Anebulo Pharmaceuticals Inc
NCA Nuveen California Municipal Value Fund
SGOL abrdn Physical Gold Shares ETF
GAB-K Gabelli Equity Trust Inc
GAB-H Gabelli Equity Trust Inc
GAB-G Gabelli Equity Trust Inc
AAL American Airlines Group Inc
ARKF ARK Fintech Innovation ETF
PNR Pentair PLC

Energy : Oil, Gas & Consumable Fuels | Small Cap Value
Based in Greece
Company profile

Tsakos Energy Navigation Ltd is a Greece-based provider of international seaborne crude oil and petroleum product transportation services. The Company operates through the maritime transportation of liquid energy-related products segment. The Company's fleet consists of 70 vessels, constituting a mix of crude tankers, product tankers, and liquefied natural gas (LNG) carriers, totaling more than 7 million dwt. It includes VLCC, Aframax, Panamax, handysize, handymax tankers, LNG carrier, and DP2 shuttle tankers, which allows the Company to serve its customers' international petroleum product and crude oil transportation needs.

This security is a preferred stock
Day's Change
0.0301 (0.12%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 5,475 shares is on pace to be much greater than TNP-F's 10-day average volume of 11,825 shares.


Editas Medicine tumbles more than 7% after announcing job cuts, restructuring

11:55 am ET January 9, 2023 (MarketWatch)

Editas Medicine Inc. [s: edit] is cutting approximately 20% of its workforce. The company reported 1,800 employees as of May 31, according to its annual report. In a statement released Monday Editas said the move will extend its cash runway into 2025. Editas' stock fell 7.7% Monday, compared with the S&P 500 Index's [s: spx] gain of 1.3%. Editas said the cuts are part of a strategic reprioritization that includes focusing resources on EDIT-301, Editas' clinical program for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia, a blood disorder that reduces production of hemoglobin. The gene editing company is also discontinuing internal investments in its inherited retinal disease programs and its wholly-owned multiplexed edited induced pluripotent stem cell derived natural killer cell programs. Additionally, Editas is restructuring its research organizations into two divisions and says it will continue advancing its cellular therapy assets through partnerships. This includes development of alpha-beta T-cell medicines with Bristol-Myers Squibb Co. [s: bmy] and gamma-delta T-cell medicines with Immatics N.V. [: imtx]. Editas also announced that Chief Scientific Officer Mark S. Shearman is stepping down from his role and will depart the company March 31. Editas has begun a search for a new CSO, the company said.

-James Rogers


(END) Dow Jones Newswires

January 09, 2023 11:55 ET (16:55 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.